Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 16, 2013 08:05 ET | Source: Immunovaccine Inc.

Immunovaccine Elects Marc Mansour, Ph.D. to Board of Directors

HALIFAX, NOVA SCOTIA--(Marketwired - Dec. 16, 2013) - Immunovaccine Inc. ("Immunovaccine" or "IMV" or "the Company") (TSX VENTURE:IMV), a clinical stage vaccine and immunotherapy company,...
December 16, 2013 08:00 ET | Source: Melinta Therapeutics, Inc.

Cempra, Inc. to Host Solithromycin and TAKSTA Clinical Update Conference Call and Webcast

CHAPEL HILL, N.C., Dec. 16, 2013 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP) today announced that it will provide an update on the clinical development of solithromycin (CEM-101) and TAKSTA™...
December 16, 2013 07:30 ET | Source: Lisata Therapeutics

NeoStem Completes Patient Enrollment in Phase 2 AMR-001 Trial for Prevention of Adverse Cardiovascular Events Following a Heart Attack

NEW YORK, Dec. 16, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, today announced completion of enrollment in its...
December 16, 2013 07:00 ET | Source: Cellceutix

Cellceutix Submits Application for IRB Review to Commence Phase 2b Clinical Trial of Novel Antibiotic Brilacidin

BEVERLY, MA--(Marketwired - Dec 16, 2013) - Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies in oncology,...
December 16, 2013 01:30 ET | Source: Galapagos NV

Galapagos selects pre-clinical candidate for cystic fibrosis

Novel potentiator shows more activity in pre-clinical studies than market leader Kalydeco® Start of Phase 1 expected before end 2014 Mechelen, Belgium; 16 December 2013 - Galapagos NV (Euronext:...
December 14, 2013 08:30 ET | Source: Myriad Genetics, Inc.

Myriad's HRD(TM) Test Significantly Predicts Response to Cisplatin Treatment in Patients With Triple Negative Breast Cancer in Second Research Study

SALT LAKE CITY, Dec. 14, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today presented clinical data at the 2013 San Antonio Breast Cancer Symposium that showed the Myriad's HRD...
December 13, 2013 08:30 ET | Source: Merrimack Pharmaceuticals

Merrimack Announces Encouraging Clinical Data From Expanded Phase 1 Study of MM-302 for the Treatment of Advanced HER2-Positive Breast Cancer

CAMBRIDGE, Mass., Dec. 13, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced Phase 1 clinical trial results for MM-302, a novel HER2-targeted liposomal doxorubicin...
December 12, 2013 12:01 ET | Source: Stellar Biotechnologies

Stellar Biotechnologies Announces Collaboration With Amaran Biotechnology, Inc.

PORT HUENEME, CA--(Marketwired - Dec 12, 2013) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH) announced today that it has entered into a...
December 12, 2013 10:44 ET | Source: Endocyte, Inc.

Endocyte Enrolls First Patient in Phase 1 Study for the Small Molecule Drug Conjugate EC1456, a Folate-Targeted Tubulysin Conjugate in Advanced Solid Tumors

WEST LAFAYETTE, Ind., Dec. 12, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company and leader in targeted small molecule drug conjugates (SMDCs) and companion imaging...
December 12, 2013 08:30 ET | Source: Celator Pharmaceuticals, Inc.

Celator(R) Pharmaceuticals Announces Positive Data and Safety Monitoring Board Recommendation for CPX-351 Phase 3 Study

EWING, N.J., Dec. 12, 2013 (GLOBE NEWSWIRE) -- Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that...